Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
November 15, 2024 01:00 ET
|
Sandoz Group
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for...
Sandoz reports third-quarter and nine-month 2024 sales
October 30, 2024 02:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and...
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
October 11, 2024 01:00 ET
|
Sandoz Group
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be...
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
August 12, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degenerationFurther enhances leading US...
Sandoz reports second-quarter sales and half-year 2024 results
August 08, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
July 25, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe)...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all...
Sandoz reports first quarter 2024 sales
May 07, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024 06:25 ET
|
Sandoz Group
All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly...